The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review

@article{Davis2019ThePB,
  title={The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review},
  author={Mellar P. Davis and Bertrand Behm and Z. Mehta and Carlos Fernandez},
  journal={American Journal of Hospice and Palliative Medicine{\textregistered}},
  year={2019},
  volume={36},
  pages={1134 - 1154}
}
Palmitoylethanolamide (PEA) is a nutraceutical endocannabinoid that was retrospectively discovered in egg yolks. Feeding poor children with known streptococcal infections prevented rheumatic fever. Subsequently, it was found to alter the course of influenza. Unfortunately, there is little known about its pharmacokinetics. Palmitoylethanolamide targets nonclassical cannabinoid receptors rather than CB1 and CB2 receptors. Palmitoylethanolamide will only indirectly activate classical cannabinoid… Expand
Knowledge and Opinion on Cannabinoids Among Orthopaedic Traumatologists

References

SHOWING 1-10 OF 244 REFERENCES
The palmitoylethanolamide family: a new class of anti-inflammatory agents?
Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy
Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial.
Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis.
Prophylactic efficacy of N-2-hydroxyethyl palmitamide (Impulsin®) in acute respiratory tract infections
Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance.
  • F. Borrelli, A. Izzo
  • Biology, Medicine
  • Best practice & research. Clinical endocrinology & metabolism
  • 2009
...
1
2
3
4
5
...